← Back to Clinical Trials
Recruiting EARLY_Phase 1 NCT06412952
68Ga-NOTA-RM26 PET/CT in Glioma Patients
Trial Parameters
Condition Glioma
Sponsor Peking Union Medical College Hospital
Study Type INTERVENTIONAL
Phase EARLY_Phase 1
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2022-10-01
Completion 2024-05-31
Interventions
68Ga-RM26
Brief Summary
The aim of this study was to investigate the value of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor (GRPR) PET tracer, in the diagnosis of high WHO grade glioma and prediction the grade of glioma using positron-emission tomography/computed tomography (PET/CT).
Eligibility Criteria
Inclusion Criteria: * suspected or confirmed untreated glioma patients * signed written consent. Exclusion Criteria: * pregnancy * breastfeeding * known allergy against Pentixafor * any medical condition that in the opinion of the investigator,may * significantly interfere with study compliance
Related Trials
NCT05770544
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients
View Trial →
NCT02800486
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treat
View Trial →
NCT04699773
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
View Trial →